Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Dextroamphetamine Saccharate And Amphetamine Aspartate And Dextroamphetamine Sulfate And Amphetamine Sulfate
Brand Name
Dextroamphetamine Saccharate And Amphetamine Aspartate And Dextroamphetamine Sulfate And Amphetamine Sulfate
Generic Name
Dextroamphetamine Saccharate And Amphetamine Aspartate And Dextroamphetamine Sulfate And Amphetamine Sulfate
Active Ingredient
Amphetamine AspartateCategory
Other
Variants
6
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Dextroamphetamine Saccharate And Amphetamine Aspartate And Dextroamphetamine Sulfate And Amphetamine Sulfate, you must consult a qualified healthcare professional.
| 2.5 mg/1 | TABLET | ORAL | 0406-8892 |
| 5 mg/1 | TABLET | ORAL | 0406-8893 |
| 7.5 mg/1 | TABLET | ORAL | 0406-8894 |
Detailed information about Dextroamphetamine Saccharate And Amphetamine Aspartate And Dextroamphetamine Sulfate And Amphetamine Sulfate
Amphetamine Aspartate is a potent central nervous system (CNS) stimulant and a key component of mixed amphetamine salt formulations. It is primarily utilized in the management of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy by modulating neurotransmitter levels in the brain.
For the treatment of ADHD in adults, the typical starting dose of mixed amphetamine salts (containing Amphetamine Aspartate) is 5 mg once or twice daily. Your healthcare provider may increase the daily dose by 5 mg at weekly intervals until the optimal therapeutic response is achieved. The maximum recommended dose for most adults is 40 mg per day, although some clinical situations may require higher doses under strict supervision. For Narcolepsy, the usual dose range is 5 mg to 60 mg per day, divided into multiple doses depending on the patient's sleep patterns and response.
In patients with severe renal impairment (GFR 15 to <30 mL/min/1.73 m²), the maximum dose should not exceed 20 mg per day for extended-release formulations. In patients with end-stage renal disease (ESRD), the use of Amphetamine Aspartate is generally not recommended as the drug is not efficiently cleared by dialysis.
While the liver is the primary site of metabolism, there are no specific quantitative guidelines for dose adjustments in hepatic impairment. However, healthcare providers usually exercise caution and may start at the lower end of the dosing spectrum due to the potential for reduced metabolic clearance.
Clinical studies for Amphetamine Aspartate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.
Amphetamine Aspartate should be taken exactly as prescribed. For immediate-release forms, the first dose is typically taken upon awakening, with subsequent doses spaced 4 to 6 hours apart. Extended-release capsules should be taken once daily in the morning. Taking this medication late in the day may result in significant insomnia (difficulty sleeping).
Extended-release capsules should generally be swallowed whole. However, for patients who cannot swallow capsules, some brands allow the capsule to be opened and the beads sprinkled onto a tablespoon of applesauce. The mixture must be consumed immediately without chewing the beads, as crushing or chewing destroys the extended-release mechanism and can lead to a dangerous "dose dump" of the medication.
If you miss a dose, take it as soon as you remember. However, if it is already late afternoon or evening, skip the missed dose and return to your regular schedule the next morning. Do not take a double dose to make up for a missed one, as this increases the risk of cardiovascular side effects and insomnia.
An overdose of Amphetamine Aspartate can be life-threatening. Signs of acute overdose include restlessness, tremor, rapid breathing (tachypnea), confusion, aggression, hallucinations, panic states, hyperpyrexia (extremely high fever), and rhabdomyolysis (muscle breakdown). Cardiovascular effects may include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps.
In the event of a suspected overdose, contact emergency services or a poison control center immediately. Treatment usually involves supportive care, administration of activated charcoal, and medications to manage blood pressure and seizures.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to severe withdrawal symptoms.
Most patients taking Amphetamine Aspartate will experience some level of side effects, particularly during the initial titration phase. Common effects include:
Amphetamine Aspartate is a powerful stimulant that must be used with extreme caution. It is not suitable for everyone, and a comprehensive cardiovascular and psychiatric screening is mandatory before the first dose. Patients must be monitored regularly for changes in blood pressure, heart rate, and mental status.
Abuse and Dependence: Amphetamines have a high potential for abuse. Use of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events.
Amphetamine Aspartate must NEVER be used in patients with the following conditions:
Amphetamine Aspartate is classified under the former FDA Pregnancy Category C. Data on its use in pregnant women are limited. However, studies suggest that infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. There is also a risk of withdrawal symptoms (neonatal abstinence syndrome) in the newborn, characterized by agitation and extreme drowsiness. Amphetamine Aspartate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Amphetamines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants (such as tachycardia, irritability, and poor weight gain), mothers taking Amphetamine Aspartate are advised to avoid breastfeeding. Consult with a pediatrician about safe infant feeding alternatives.
Amphetamine Aspartate is FDA-approved for the treatment of ADHD in children as young as 3 years old. However, it is not recommended for children under 3. The primary concern in pediatric use is the suppression of growth. Clinical data suggests that children on long-term stimulant therapy may experience a temporary slowing in height and weight gain. Healthcare providers must monitor growth parameters closely and may suggest "medication holidays" (stopping the drug during summer breaks) to allow for catch-up growth.
Amphetamine Aspartate is a potent inducer of monoamine release. Its primary molecular target is the Trace Amine-Associated Receptor 1 (TAAR1), a G protein-coupled receptor located in the presynaptic terminal. Upon binding, it triggers the phosphorylation of the Dopamine Transporter (DAT), causing it to function in reverse. Simultaneously, it enters the neuron via DAT and inhibits the Vesicular Monoamine Transporter 2 (VMAT2), which normally packages dopamine into vesicles. This causes a massive efflux of dopamine and norepinephrine into the synapse, enhancing signal transmission in the reward and attention centers of the brain.
The pharmacodynamic effects of Amphetamine Aspartate include increased alertness, decreased fatigue, and improved mood. There is a clear dose-response relationship, where higher doses lead to greater neurotransmitter release but also a higher risk of side effects like hypertension. Tolerance to the euphoric and appetite-suppressant effects often develops within weeks, whereas the therapeutic effects for ADHD tend to remain stable over longer periods.
| Parameter | Value |
Common questions about Dextroamphetamine Saccharate And Amphetamine Aspartate And Dextroamphetamine Sulfate And Amphetamine Sulfate
Amphetamine Aspartate is primarily used as a central nervous system stimulant to treat Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. In ADHD, it helps improve focus, attention, and impulse control by increasing dopamine and norepinephrine levels in the brain. For narcolepsy, it is used to promote wakefulness and prevent sudden sleep attacks during the day. It is most commonly found as a component of mixed amphetamine salt medications like Adderall. Always use this medication under the strict supervision of a qualified healthcare professional.
The most frequently reported side effects include a significant decrease in appetite, dry mouth, insomnia, and an increased heart rate. Many patients also experience stomach pain, nausea, or weight loss, especially during the first few weeks of treatment. Some individuals may feel irritable or anxious as the medication wears off in the evening. Most of these side effects are dose-dependent and may improve as your body adjusts to the medication. If side effects become severe or persistent, you should contact your doctor to discuss a dosage adjustment.
No, you should strictly avoid consuming alcohol while taking Amphetamine Aspartate. Alcohol can interfere with the way the medication is released in your body, potentially leading to a dangerously high concentration of the drug in your bloodstream. Furthermore, stimulants can mask the intoxicating effects of alcohol, which may lead you to drink more than you realize, increasing the risk of alcohol poisoning. Combining the two also puts significant strain on the cardiovascular system. Always prioritize your safety by avoiding alcohol during treatment.
Amphetamine Aspartate is generally not recommended during pregnancy unless the benefits clearly outweigh the risks. Research indicates that infants born to mothers who use amphetamines may have a higher risk of premature birth, low birth weight, and withdrawal symptoms after delivery. There is also a theoretical risk of developmental issues, although human data is limited. If you are pregnant or planning to become pregnant, it is vital to discuss alternative treatments with your healthcare provider. They will help you weigh the risks of untreated ADHD against the potential risks to the fetus.
Immediate-release versions of Amphetamine Aspartate typically begin working within 30 to 60 minutes of ingestion. Peak effects are usually reached around 3 hours after taking the dose and last for approximately 4 to 6 hours. Extended-release formulations take about the same time to start working but are designed to provide a steady therapeutic effect for up to 10 or 12 hours. Because it works quickly, many patients notice an improvement in focus and a reduction in hyperactivity on the very first day of treatment. However, finding the optimal dose for long-term management may take several weeks.
Stopping Amphetamine Aspartate abruptly, especially after long-term use at high doses, can lead to a 'crash' or withdrawal syndrome. Symptoms of sudden discontinuation include extreme fatigue, depression, irritability, and increased appetite. In some cases, patients may experience vivid or unpleasant dreams and significant sleep disturbances. To avoid these effects, healthcare providers usually recommend a gradual tapering of the dose. Never stop your medication without first consulting your doctor to ensure a safe transition.
If you miss a dose, take it as soon as you remember, provided it is not late in the day. Because this medication is a stimulant, taking a dose in the late afternoon or evening can cause significant insomnia. If it is already late, it is usually better to skip the missed dose and resume your normal schedule the following morning. Never take two doses at once to make up for a missed one, as this can lead to dangerous increases in blood pressure and heart rate. Consistency is key to managing ADHD symptoms effectively.
No, Amphetamine Aspartate is much more likely to cause weight loss rather than weight gain. As a potent stimulant, it significantly suppresses appetite and increases the body's metabolic rate. In children, this can sometimes lead to a temporary slowing of growth, which is why doctors monitor height and weight so closely. If weight loss becomes a concern, your doctor may suggest taking the medication after meals or implementing 'medication holidays.' Significant or rapid weight loss should always be reported to your healthcare provider.
Amphetamine Aspartate has many potential drug interactions, some of which can be life-threatening. It should never be taken with MAO inhibitors, and it must be used cautiously with antidepressants like SSRIs or SNRIs due to the risk of Serotonin Syndrome. It can also interact with blood pressure medications, antacids, and even certain cold medicines. Always provide your doctor and pharmacist with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. This allows them to screen for dangerous interactions before you start the stimulant.
Yes, Amphetamine Aspartate is widely available as a generic medication, usually as part of a 'Mixed Amphetamine Salts' formulation. Generic versions are required by the FDA to have the same active ingredients, strength, and dosage form as the brand-name versions (like Adderall). Choosing the generic version can significantly reduce the cost of treatment for many patients. However, some individuals may find that they respond slightly differently to different generic manufacturers. Consult your pharmacist if you have questions about the specific generic version you receive.
Other drugs with the same active ingredient (Amphetamine Aspartate)
Adderall
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-release
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, And Amphetamine Sulfate Extended-release
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Tablets,cii
> Warning: Stop taking Amphetamine Aspartate and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of Amphetamine Aspartate may lead to several long-term considerations:
Amphetamine Aspartate carries a prominent FDA Black Box Warning regarding its high potential for abuse and administration for prolonged periods may lead to drug dependence. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others. Furthermore, misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.
Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
Healthcare providers will typically require the following monitoring:
Amphetamine Aspartate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles. While it often improves focus, the potential for dizziness or "crashing" as the medication wears off can affect reaction times. Use caution until you know how the medication affects you.
Alcohol should be strictly avoided. Alcohol can alter the way the body releases and absorbs Amphetamine Aspartate, particularly extended-release versions, leading to unpredictable blood levels. Furthermore, stimulants can mask the sedative effects of alcohol, increasing the risk of alcohol poisoning or risky behavior.
Do not stop taking Amphetamine Aspartate abruptly after long-term use. Sudden discontinuation can lead to "amphetamine crash," characterized by extreme fatigue, depression, and sleep disturbances. Your doctor will provide a tapering schedule to gradually reduce the dose.
> Important: Discuss all your medical conditions, especially any history of heart problems or mental health issues, with your healthcare provider before starting Amphetamine Aspartate.
Amphetamines can cause a significant elevation in plasma corticosteroid levels, with the greatest increase occurring in the evening. They may also interfere with urinary steroid determinations. If you are undergoing a drug screen, Amphetamine Aspartate will result in a positive test for amphetamines; always provide your prescription documentation to the testing laboratory.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as well as any changes in your diet.
Conditions requiring careful risk-benefit analysis include:
Patients who have shown a hypersensitivity or allergic reaction to other sympathomimetic amines (such as pseudoephedrine or methylphenidate) should use Amphetamine Aspartate with extreme caution, as cross-sensitivity is possible. Symptoms of an allergic reaction include rash, hives, or swelling.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Amphetamine Aspartate to ensure it is safe for your specific health profile.
Elderly patients (65+) are at a higher risk for cardiovascular side effects and may have reduced renal function, which can lead to drug accumulation. Stimulants can also worsen pre-existing sleep disturbances or agitation in older adults. Lower starting doses and frequent monitoring are mandatory for this population.
Since the kidneys are responsible for the excretion of amphetamine, any reduction in GFR (Glomerular Filtration Rate) will result in higher drug levels. For patients with a GFR between 15 and 30, the dose of extended-release forms should be capped at 20 mg. It is not recommended for those with a GFR below 15.
While specific dose adjustments are not codified, the liver's role in the oxidative metabolism of amphetamine means that patients with severe cirrhosis or hepatitis may experience prolonged drug effects. Monitoring for toxicity is essential.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure safety and efficacy.
| Bioavailability | 75% - 80% |
| Protein Binding | ~20% |
| Half-life | 9 - 14 hours (Adults) |
| Tmax | 3 hours (IR), 7 hours (ER) |
| Metabolism | Hepatic (CYP2D6) |
| Excretion | Renal (pH dependent) |
Amphetamine Aspartate (C13H19NO4) is the aspartic acid salt of the racemic mixture of d-amphetamine and l-amphetamine. It has a molecular weight of approximately 269.3 g/mol. It appears as a white, odorless crystalline powder that is soluble in water. The aspartate salt is used specifically to modulate the solubility and release characteristics of the amphetamine molecule within a multi-salt matrix.
Amphetamine Aspartate belongs to the CNS Stimulant class, specifically the Amphetamine sub-class. Related medications include Dextroamphetamine Sulfate, Amphetamine Sulfate, and Lisdexamfetamine (Vyvanse).